Target
Histamine H1 receptor
8 abstracts
Abstract
An open-label randomized trial comparing addition of olanzapine 5 mg versus olanzapine 10 mg as anti-emetic to standard anti-emetic regime for doxorubicin or epirubicin and cyclophosphamide in breast cancer.Org: Command Hospital (AF), Central Regional Referral Hospital,
Abstract
Guideline-concordant use of olanzapine as part of a 4-drug antiemetic regimen for high emetic risk chemotherapy across the state of Michigan.Org: Michigan Oncology Quality Consortium, University of Michigan,
Abstract
Incidence of infusion related reactions of daratumumab-hyaluronidase-fihj: Pre-post intervention study of premedication omission.Org: University of Chicago Medical Center, Chicago, IL, Center for Data Intensive Science at the University of Chicago, University of Chicago,
Abstract
Real-world analysis of cardiac, gastrointestinal, and hematologic toxicities between commonly used antiemetics in everyday oncology clinical practice.Org: Louisiana State University in Shreveport, Feist-Weiller Cancer Center at LSUHSC-Shreveport, LSU Health Shreveport,
Abstract
A phase III, double-blind, non-inferiority, randomized controlled trial of antiemetic prophylaxis for highly emetogenic chemotherapy without dexamethasone: CINV POD study.Org: Cancer Institute of Jiangsu Province,
Abstract
ACCLAIM-1 dose escalation: Determination of quaratusugene ozeplasmid and osimertinib recommended phase 2 dose (RP2D).Org: Valkyrie Clinical Trials, Inc, Rocky Mountain Cancer Centers, Millennium Oncology, Virginia Cancer Specialists, Genprex,
Abstract
The efficacy of cationic amphiphilic antihistamines on outcomes of patients with pancreatic ductal adenocarcinoma.Org: Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, National Taiwan University Hospital Yunlin Branch, Taipei, Taiwan,